Updated 11/3/2018

--------------------------------

BIO-Europe November 5-7, 2018; Copenhagen, Denmark

Resverlogix and Zenith are on the BIO Europe presentation schedule for Tuesday November 6 at 17:00 and 9:30 Copenhagen time, respectively. However, this event not listed on Resverlogix or Zenith website or in the Resverlogix November 2018 Fact Sheet as of this posting.

AHA 2018 (American Heart Association) November 10-12, 2018; Chicago, IL

Presentation #1 November 11, from 10:30 AM to 11:45 AM CST: "Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study." Non late-breaking abstracts will be available online Monday, November 5, 5:00 am ET/ 4:00 am CT. Poster will be posted on RVX website here at the appropriate time. 

Presentation #1 November 12, from 1:00 PM – 2:15 PM CST: "Apabetalone (RVX-208) Suppresses Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and LPS-Challenged Mouse Liver and Monocyte Adhesiveness to Activated Endothelial Cells." Non late-breaking abstracts will be available online Monday, November 5, 5:00 am ET/ 4:00 am CST. Poster will be posted on RVX website here at the appropriate time.

H1 2019 events to keep an eye on

Biotech Showcase January 7-9, 2018; San Francisco, CA

American College Cardiology (ACC) March 16-18, 2019; New Orleans, LA (note: Late-Breaking Clinical Trial Submissions are open Wednesday, Oct. 24 – Wednesday, Dec. 5, 2018). This is prime time possiblility for BETonMACE. First big cardio conference of the new year. Many big cardio outcomes trials present full trial results here.

BIO-Europe Spring March 25-27, 2018; Vienna, Austria

Vascular Discovery: From Genes to Medicine (Formerly ATVB:PVD): May 2019

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA): June 2019

BIO-International June 2019

American Diabetes Association (ADA) June 2019